<DOC>
	<DOCNO>NCT00623233</DOCNO>
	<brief_summary>To determine long Gemcitabine Bevacizumab stop cancer grow patient advanced breast cancer .</brief_summary>
	<brief_title>Gemcitabine Plus Bevacizumab Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Must female great equal 18 yr age Participants must confirm cancer measurable evaluable , locally recurrent metastatic disease . Participants must receive taxane neoadjuvant and/or adjuvant therapy Participants may receive prior hormone therapy locally recurrent metastatic disease Participants breast cancer overexpressing Human Epidermal growth factor Receptor 2 ( HER2 ) gene amplification Prior chemotherapy target therapy metastatic breast cancer Prior treatment gemcitabine , trastuzumab , lapatinib bevacizumab set History , active brain mets Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior treatment , anticipation need major surgical procedure course study Prior history high blood pressure crisis Have serious , nonhealing wound , ulcer , bone fracture</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Breast Neoplasm</keyword>
</DOC>